Parental and Other Factors Associated with Hydroxyurea Use for Pediatric Sickle Cell Disease

BACKGROUND: Hydroxyurea (HU) is highly effective treatment for Sickle Cell Disease (SCD). While pediatric use of HU is accepted clinical practice, barriers to use may impede its potential benefit. PROCEDURE: A survey of parents of children ages 5–17 years with SCD was performed across five instituti...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Oyeku, Suzette O., Driscoll, M. Catherine, Cohen, Hillel W., Trachtman, Rebecca, Pashankar, Farzana, Mullen, Craig, Giardina, Patricia J., Velazco, Nerissa, Racine, Andrew D., Green, Nancy S.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3625668/
https://ncbi.nlm.nih.gov/pubmed/23129068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24381
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items